BFRI
Biofrontera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.81
−1.94%Year over year
Reported trailing growth
- Revenue
- +17.8%
- EBITDA
- +64.5%
- EBIT
- +73.2%
- EPS
- +76.0%
- Free cash flow
- +15.6%
- Operating cash flow
- +15.6%
Forward estimates
Based on analyst estimates
- Revenue
- +4.4%
- EBITDA
- +171.6%
- EPS
- +129.2%
Three-year CAGR
- Revenue
- +13.3%
- EBITDA
- +36.4%
- EBIT
- +46.8%
- Net income
- +40.7%
- EPS
- +67.7%
- Free cash flow
- -29.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026